A phase 1 study with the novel B-cell lymphoma 2 (BCL2) inhibitor BGB-11417 as monotherapy or in combination with zanubrutinib in patients with B-cell malignancies: Preliminary data

Authors: Chan Y. Cheah[1,2,3]; Stephen Opat[4,5]; Masa Lasica[6]; Emma Verner[7,8]; Peter J. Browett[9]; Henry Chan[10]; Jacob D. Soumerai[11]; Eva González Barca[12]; James Hilger[13]; Yiqian Fang[13]; David Simpson[13]; Constantine S. Tam[14,15,16,17]

Affiliations: [1]Sir Charles Gairdner Hospital and Pathwest Laboratory Medicine, Nedlands, Western Australia, Australia; [2]Medical School, University of Western Australia, Crawley, Western Australia, Australia; [3]Linear Clinical Research, Nedlands, Western Australia, Australia; [4]Monash Health, Clayton, Victoria, Australia; [5]Monash University, Clayton, Victoria, Australia; [6]St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; [7]Concord Repatriation General Hospital, Concord, New South Wales, Australia; [8]University of Sydney, Sydney, New South Wales, Australia; [9]Auckland City Hospital, Auckland, New Zealand; [10]North Shore Hospital Auckland, New Zealand; [11]Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA; [12]Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain; [13]BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA, USA; [14]Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; [15]University of Melbourne, Parkville, Victoria, Australia; [16]St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia; [17]Royal Melbourne Hospital, Parkville, Victoria, Australia

ABSTRACT

Aim: BCL2 is aberrantly expressed in many hematologic malignancies and promotes tumorigenesis. BGB-11417-101 (NCT04277637) is an ongoing, first-in-human, phase 1/1b dose-escalation/expansion study evaluating safety, tolerability, maximum tolerated dose (MTD), and recommended phase 2 dose of oral BGB-11417, a potent, highly selective BCL2 inhibitor, alone or in combination with zanubrutinib, a BTK inhibitor, in patients with relapsed/refractory (R/R) B-cell malignancies.

Method: BGB-11417 (40, 80, 160, 320, or 640mg once daily [QD]) with weekly or daily ramp-up to target dose) was given as monotherapy or combined with zanubrutinib (320mg QD or 160mg twice daily) 8-12 weeks before BGB-11417. Dose-limiting toxicity was evaluated by Bayesian logistic regression. Adverse events (AEs) were reported per CTCAE v5.0.

Results: As of 17Dec2021, 58 patients received BGB-11417 (monotherapy=32; combination=26). Of patients receiving monotherapy, 26 with non-Hodgkin lymphoma (NHL) received ≤640mg and 6 with CLL/SLL received ≤160mg; for those

receiving combination treatment, 19 with R/R CLL/SLL received BGB-11417 ≤160mg and 7 with R/R MCL received ≤80mg. MTD has not been reached. Median follow-up was 3.9 months (range=0.1-20.4). Two grade ≥3 AEs (neutropenia=1, autoimmune haemolytic anaemia=1) occurred in combination cohorts. 20 patients discontinued treatment (disease progression=17; AE=1; other=2). One high-risk patient with CLL (monotherapy) had laboratory tumour lysis syndrome (<2%) that resolved without intervention. Early data show that most patients had reduction in sum of product of perpendicular diameters; 2 patients with NHL (monotherapy) had responses (complete response=1). Patients with CLL/SLL had notable reductions in absolute lymphocyte counts at doses ≥1mg; 2 responses (≥partial response) occurred with monotherapy and 12 with combination (≥partial response + lymphocytosis).

Conclusion: Preliminary findings suggest BGB-11417 has promising efficacy and is tolerable at ≤640mg as monotherapy and ≤160mg combined with zanubrutinib. Dose escalation continues as MTD has not been reached. Enrolment is ongoing, data for Waldenström macroglobulinemia and treatment-naïve CLL/SLL are forthcoming.